MA40042B1 - Protéines prohémostatiques pour le traitement de saignement - Google Patents

Protéines prohémostatiques pour le traitement de saignement

Info

Publication number
MA40042B1
MA40042B1 MA40042A MA40042A MA40042B1 MA 40042 B1 MA40042 B1 MA 40042B1 MA 40042 A MA40042 A MA 40042A MA 40042 A MA40042 A MA 40042A MA 40042 B1 MA40042 B1 MA 40042B1
Authority
MA
Morocco
Prior art keywords
bleeding
treatment
proteins
prohemostatic
subject
Prior art date
Application number
MA40042A
Other languages
English (en)
Inventor
Daniël Verhoef
Pieter H Reitsma
Mettine H A Bos
Original Assignee
Academisch Ziekenhuis Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Ziekenhuis Leiden filed Critical Academisch Ziekenhuis Leiden
Publication of MA40042B1 publication Critical patent/MA40042B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des polypeptides fxa recombinés qui peuvent être utilisés comme antidotes pour neutraliser complètement ou en partie un effet anticoagulant d'un inhibiteur de coagulation chez un sujet, de préférence un inhibiteur direct du facteur xa. L'invention concerne des protéines recombinées du facteur xa et une méthode permettant de neutraliser complètement ou en partie un effet anticoagulant d'un inhibiteur de coagulation chez un sujet.
MA40042A 2014-05-26 2015-05-26 Protéines prohémostatiques pour le traitement de saignement MA40042B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14169895 2014-05-26
PCT/NL2015/050377 WO2015183085A1 (fr) 2014-05-26 2015-05-26 Protéines prohémostatiques pour le traitement d'une hémorragie

Publications (1)

Publication Number Publication Date
MA40042B1 true MA40042B1 (fr) 2020-08-31

Family

ID=50774744

Family Applications (2)

Application Number Title Priority Date Filing Date
MA051688A MA51688A (fr) 2014-05-26 2015-05-26 Protéines prohémostatiques pour le traitement de saignement
MA40042A MA40042B1 (fr) 2014-05-26 2015-05-26 Protéines prohémostatiques pour le traitement de saignement

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA051688A MA51688A (fr) 2014-05-26 2015-05-26 Protéines prohémostatiques pour le traitement de saignement

Country Status (24)

Country Link
US (5) US10537618B2 (fr)
EP (2) EP3744840A1 (fr)
JP (3) JP6640198B2 (fr)
KR (2) KR102245264B1 (fr)
CN (1) CN106536566A (fr)
AU (2) AU2015268149B2 (fr)
CA (1) CA2949349A1 (fr)
DK (1) DK3149163T3 (fr)
EA (2) EA037991B1 (fr)
ES (1) ES2813440T3 (fr)
HR (1) HRP20201311T1 (fr)
HU (1) HUE052098T2 (fr)
IL (2) IL249132B (fr)
LT (1) LT3149163T (fr)
MA (2) MA51688A (fr)
MX (2) MX378899B (fr)
NZ (1) NZ727444A (fr)
PL (1) PL3149163T3 (fr)
PT (1) PT3149163T (fr)
RS (1) RS60706B1 (fr)
SG (2) SG11201609811TA (fr)
SI (1) SI3149163T1 (fr)
WO (1) WO2015183085A1 (fr)
ZA (1) ZA201608017B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX378899B (es) * 2014-05-26 2025-03-10 Academisch Ziekenhuis Leiden Proteinas prohemostaticas para el tratamiento de hemorragias.
CN108486197B (zh) * 2018-03-06 2021-10-22 爱斯特（成都）生物制药股份有限公司 高纯度依度沙班中间体的制备方法
GB202408056D0 (en) * 2024-06-06 2024-07-24 Cambridge Entpr Ltd Anticoagulant protein molecules and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
EP0785273A1 (fr) 1990-11-26 1997-07-23 Genetics Institute, Inc. Enzyme de conversion d'acides aminés basiques couplés et séquence d'ADN codant pour cette enzyme
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
EP1728798A1 (fr) 2005-06-01 2006-12-06 ZLB Behring GmbH Polypeptides du facteur X de la coagulation avec propiertés d'activation modifiées
MX336958B (es) * 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (fr) * 2006-02-21 2007-08-22 CSL Behring GmbH Polypeptides du facteur de coagulation X avec des propriétés d'activation modifiées
EP2481797A1 (fr) * 2007-04-13 2012-08-01 Catalyst Biosciences, Inc. Polypeptides de facteur VII modifiés et leurs utilisations
EP2193196B1 (fr) 2007-09-28 2016-07-13 Portola Pharmaceuticals, Inc. Antidotes pour les inhibiteurs du facteur xa et leur procédé d'utilisation
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
JP6163304B2 (ja) 2009-07-15 2017-07-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子インヒビターの解毒剤の単位用量処方物およびその使用方法
SG11201500579SA (en) * 2012-07-25 2015-02-27 Catalyst Biosciences Inc Modified factor x polypeptides and uses thereof
KR20150103205A (ko) 2013-01-31 2015-09-09 화이자 인코포레이티드 인자 Xa 억제를 길항하기 위한 조성물 및 방법
US10119101B2 (en) 2014-04-28 2018-11-06 Ecolab Usa Inc. Method of minimizing enzyme based aerosol mist using a pressure spray system
MX378899B (es) * 2014-05-26 2025-03-10 Academisch Ziekenhuis Leiden Proteinas prohemostaticas para el tratamiento de hemorragias.

Also Published As

Publication number Publication date
SG10201906329VA (en) 2019-08-27
ES2813440T3 (es) 2021-03-23
IL277377B (en) 2021-10-31
EP3744840A1 (fr) 2020-12-02
AU2015268149B2 (en) 2021-03-11
WO2015183085A1 (fr) 2015-12-03
JP2022134139A (ja) 2022-09-14
CA2949349A1 (fr) 2015-12-03
PL3149163T3 (pl) 2020-12-28
IL277377A (en) 2020-11-30
EA202190813A1 (ru) 2021-12-31
ZA201608017B (en) 2019-04-24
AU2015268149A1 (en) 2016-12-08
JP2017522900A (ja) 2017-08-17
US20240390467A1 (en) 2024-11-28
RS60706B1 (sr) 2020-09-30
KR20170020332A (ko) 2017-02-22
US12083170B2 (en) 2024-09-10
SI3149163T1 (sl) 2020-10-30
EA201692161A1 (ru) 2017-08-31
MA51688A (fr) 2020-12-02
US20200138916A1 (en) 2020-05-07
MX2020013410A (es) 2021-02-26
EA037991B1 (ru) 2021-06-21
MX378899B (es) 2025-03-10
LT3149163T (lt) 2020-09-25
AU2021203838B2 (en) 2023-03-02
US10537618B2 (en) 2020-01-21
KR102351728B1 (ko) 2022-01-14
US20170157223A1 (en) 2017-06-08
IL249132B (en) 2020-09-30
JP2020062039A (ja) 2020-04-23
US11304995B2 (en) 2022-04-19
AU2021203838A1 (en) 2021-07-08
HUE052098T2 (hu) 2021-04-28
JP6640198B2 (ja) 2020-02-05
SG11201609811TA (en) 2016-12-29
NZ727444A (en) 2021-12-24
DK3149163T3 (da) 2020-08-31
NZ764611A (en) 2024-07-05
EP3149163A1 (fr) 2017-04-05
BR112016027649A2 (pt) 2017-08-15
IL249132A0 (en) 2017-01-31
JP7535849B2 (ja) 2024-08-19
PT3149163T (pt) 2020-09-03
EP3149163B1 (fr) 2020-06-03
US20200138917A1 (en) 2020-05-07
MX2016015567A (es) 2017-06-29
HRP20201311T1 (hr) 2020-12-11
US11357836B2 (en) 2022-06-14
CN106536566A (zh) 2017-03-22
KR102245264B1 (ko) 2021-04-28
US20220288172A1 (en) 2022-09-15
KR20210054573A (ko) 2021-05-13

Similar Documents

Publication Publication Date Title
EA201991862A1 (ru) Композиции и способы, предназначенные для лечения гемоглобинопатий
EA201791866A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
MY203971A (en) Anti-lag-3 antibodies and compositions
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201890051A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
EA201691470A1 (ru) Белки, связывающие калликреин плазмы, и их применение для лечения наследственного ангионевротического отека
EA201790259A1 (ru) СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА
EA202091865A1 (ru) Композиции и способы для снижения экспрессии tau
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
WO2017015622A8 (fr) Protéines de liaison à gdf11 et leurs utilisations
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MX2022015248A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA201691677A1 (ru) Генетические локусы, связанные с повышенной фертильностью у маиса
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода